AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $16.17.
Several brokerages have weighed in on ABCL. Benchmark upgraded shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Thursday, February 22nd. Stifel Nicolaus dropped their target price on shares of AbCellera Biologics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 21st. Finally, KeyCorp dropped their target price on shares of AbCellera Biologics from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, May 8th.
Check Out Our Latest Stock Report on AbCellera Biologics
Hedge Funds Weigh In On AbCellera Biologics
AbCellera Biologics Stock Down 1.3 %
Shares of NASDAQ:ABCL opened at $3.02 on Thursday. AbCellera Biologics has a 12 month low of $2.98 and a 12 month high of $8.05. The company’s fifty day simple moving average is $3.82 and its 200 day simple moving average is $4.65. The firm has a market cap of $888.03 million, a price-to-earnings ratio of -5.81 and a beta of 0.45.
AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. AbCellera Biologics had a negative net margin of 410.47% and a negative return on equity of 12.61%. The firm had revenue of $9.95 million for the quarter, compared to analyst estimates of $10.73 million. During the same period in the previous year, the business earned ($0.14) EPS. The company’s revenue was down 18.4% compared to the same quarter last year. Research analysts expect that AbCellera Biologics will post -0.6 earnings per share for the current fiscal year.
About AbCellera Biologics
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Read More
- Five stocks we like better than AbCellera Biologics
- How to Invest in the FAANG Stocks
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Industrial Products Stocks Investing
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.